Abstract:James A Katz, 1 Paul M Karpecki, 2 Alexandra Dorca, 3 Sima Chiva-Razavi, 4 Heather Floyd, 4 Elizabeth Barnes, 4 Mark Wuttke, 4 Eric Donnenfeld 5 1 The Midwest Center for Sight, Des Plaines, IL, USA; 2 Kentucky Eye Institute, Lexington, KY, USA; 3 Favoris AG, Basel, Switzerland; 4 Novartis Pharma AG, Basel, Switzerland; 5 Ophthalmic Consultants of Long Island, Garden City, NY, USA Correspondence: Eric Donnenfeld Ophthalmic Consultants of Long Island, 711 Stewart Avenue, Suite 160, Garden City, NY, 11530, USA Email Presbyopia is a common age-related vision disorder characterized by a progressive inability to focus on near objects. If uncorrected or under-corrected, presbyopia can significantly impact patients' quality of life. Presbyopia represents an area of considerable unmet need due to its rising prevalence worldwide as the population ages, the high proportion of under-treated individuals in some parts of the world, and the limitations of currently available corrective methods. Progressive or bifocal spectacles are associated with peripheral blur, a restricted visual field and impaired depth perception, which have been linked to an increased risk of falls in the elderly. Contact lens options can be difficult to maintain due to the development of age-related dry eye symptoms and reduced manual dexterity. Other corrective methods involve surgical interventions that modify the optics of the cornea, replace the crystalline lens, or attempt to restore active accommodation. While patients undergoing surgery report satisfactory outcomes post-operatively, many of them eventually require reading glasses. Non-invasive therapies with novel mechanisms of action are currently being investigated; these include miotic agents and UNR844, a lipoic acid choline ester. In this narrative review, available evidence on presbyopia prevalence, quality of life impact and risk factors are described, with a focus on observational studies in non-clinical settings. The diagnosis pathway and patient journey in presbyopia are outlined, and various treatment options are analyzed. The data reviewed herein reveals significant gaps in the provision of vision correction for this common condition, with a paucity of effective, non-invasive treatment options broadly accessible to presbyopic individuals. Keywords: presbyopia, epidemiology, patient characterization, vision correction, pharmacological therapies This review was carried out to i) explore available evidence on the causes and risk factors of presbyopia, ii) summarize how the condition is currently diagnosed and managed, including residual unmet needs and iii) provide an overview of potential future treatment options that are currently in development. Presbyopia is an age-related decline in the ability to focus on near tasks, thought to be caused by a loss of flexibility, increase in size and hardening of the lens and/or the muscle fibers surrounding the lens inside the eye. Our research found that the onset of presbyopia may be earlier in women and in individuals who live closer to the equator. Presbyopia onset may also be influenced by an individual's distance glasses prescription. We discovered that presbyopia is typically diagnosed around 50 years of age, with optometrists being the major providers of vision correction. However, current treatment options for presbyopia, which include glasses, contact lenses and surgery, mostly manage the symptom of blurred near vision, without addressing the underlying cause of the condition. This review highlights the need for effective, broadly accessible, non-invasive presbyopic treatment options. Presbyopia is a common, age-related vision disorder characterized by a progressive inability to focus on near objects. Presbyopia is hypothesized to be caused by either a weakening of the ciliary muscles or a loss of lens elasticity preventing focal point change. 1 , 2 While the etiology of this condition is not fully elucidated, recent research suggests that an increase in lens rigidity is the primary causative mechanism. 3 , 4 Although corrective measures are available to restore near vision, access to treatment (most often in the form of reading glasses) is limited in some parts of the world. In 2015, 826 million of the 1.8 billion people estimated to have functional presbyopia were found to be living with uncorrected near vision impairment because they had no access to vision correction or were utilizing inadequate correction. 5 Without optical correction, presbyopia can have multiple effects on quality of life, such as problems reading (inability to read fine print, ne -Abstract Truncated-

Lens disorders in degenerative myopia. Treatment options

OPTH_A_259011 2167..2178

Retinal status in moderate myopia and age-related macular degeneration. Management strategies

Optics of spectacle lenses intended to treat myopia progression

Complications of high myopia: An update from clinical manifestations to underlying mechanisms

Presbyopia – A Review of Current Treatment Options and Emerging Therapies

High myopia: Reviews of myopia control strategies and myopia complications

Long-term progression of myopic maculopathy in degenerative myopia as imaged by SD-OCT and IR imaging

Myopia: Mechanisms and Strategies to Slow Down Its Progression

IMI Prevention of Myopia and Its Progression

Juvenile myopia progression, risk factors and interventions

Medical technology for the management of myopia progression

Retinal clinical and morphofunctional changes in high myopia in combination with age-related macular degeneration of different stages

Oxidative stress and antioxidants in cataract development

The Complications of Myopia: A Review and Meta-Analysis

Challenges of refractive cataract surgery in the era of myopia epidemic: a mini-review

Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute

“Important Players” in the Development of Age-Related Cataracts (Literature Review)

Optic treatments to myopia management

Current Trends in the Pharmacotherapy of Cataracts

Low vision rehabilitation program in patients with myopic macular degeneration: A case series